1. Home
  2. PHUN vs VTGN Comparison

PHUN vs VTGN Comparison

Compare PHUN & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phunware Inc.

PHUN

Phunware Inc.

HOLD

Current Price

$2.06

Market Cap

43.0M

Sector

Technology

ML Signal

HOLD

Logo VistaGen Therapeutics Inc.

VTGN

VistaGen Therapeutics Inc.

HOLD

Current Price

$0.24

Market Cap

25.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHUN
VTGN
Founded
2009
1998
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.0M
25.3M
IPO Year
2016
2014

Fundamental Metrics

Financial Performance
Metric
PHUN
VTGN
Price
$2.06
$0.24
Analyst Decision
Buy
Hold
Analyst Count
2
3
Target Price
$7.25
$0.90
AVG Volume (30 Days)
89.5K
2.9M
Earning Date
05-14-2026
06-16-2026
Dividend Yield
N/A
N/A
EPS Growth
39.36
N/A
EPS
N/A
N/A
Revenue
$30,883,000.00
N/A
Revenue This Year
$89.86
$124.49
Revenue Next Year
N/A
$353.99
P/E Ratio
N/A
N/A
Revenue Growth
15.57
N/A
52 Week Low
$1.56
$0.20
52 Week High
$3.13
$5.14

Technical Indicators

Market Signals
Indicator
PHUN
VTGN
Relative Strength Index (RSI) 46.79 38.43
Support Level $2.00 $0.21
Resistance Level $2.11 $0.66
Average True Range (ATR) 0.08 0.02
MACD -0.01 0.01
Stochastic Oscillator 29.17 11.49

Price Performance

Historical Comparison
PHUN
VTGN

About PHUN Phunware Inc.

Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services. Development services for customers who wish to have a customized application experience; and In-app advertising services for mobile audience building, user acquisition, application discovery, audience engagement and monetization.

About VTGN VistaGen Therapeutics Inc.

Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.

Share on Social Networks: